PRN: Three Day Pharmacovigilance Course (London, United Kingdom - December 4-5-6, 2017) - Research and Markets

20/apr/2017 16:30:34 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Three Day Pharmacovigilance Course (London, United Kingdom - December 4-5-6, 2017) - Research and Markets

 
[20-April-2017]
 

DUBLIN, Apr. 20, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Pharmacovigilance" conference to their offering.

Research and Markets Logo

This course aims to provide basic training for those concerned with pharmacovigilance. New entrants as well as experienced operators in drug safety monitoring will benefit from the mixture of scientific knowledge and practical guidance. In addition, detailed information will be provided on regulatory developments in pharmacovigilance in Europe, the USA, and Japan.

This three-day introductory course is aimed at personnel in research and development departments, adverse reaction monitoring units, regulatory affairs and registration departments; pharmaceutical physicians and drug safety officers. It will also be of direct benefit to all those who are involved and interested in the daily practice of pharmacovigilance.

Key Topics to Be Addressed at the Pharmacovigilance Conference:

- Principles of Pharmacovigilance and Data Resources
- Risk Management and Risk Minimisation
- Causality Assessment: Clinical Diagnosis of Adverse Events
- PASS and PAES Studies
- Regulatory Framework
- European Post-Marketing Pharmacovigilance Regulations
- Pharmacoepidemiological Studies
- Evolution of PSURs, PBRERs and DSURs - Pro-active Pharmacovigilance Pre- and Post Marketing
- Clinical Trial ADR reporting requirements
- Risk/Benefit Assessment
- Drug Surveillance in countries outside Europe
- Examples of pharmacoepidemiological studies used in risk management
- Introduction to Signal detection
- Introduction to Risk Management plans
- Practical Pharmacovigilance Workshop

Agenda:

Day 1 Schedule

09.00 Registration and coffee

09.30 Principles of Ph! armacovigilance and Data Resources

- Basic principles of monitoring drug safety
- An overview of methodology
- Data resources available for monitoring and evaluating drug safety
- Responding to drug safety signals

Risk Management and Risk Minimisation: Basic Principles

- Basic principles
- Proactive strategies
- Principles of risk minimisation
- PASS and PAES studies

Causality Assessment: Clinical Diagnosis of Adverse Events

- The principles of causality assessment with practical examples
- Medical evaluation of individual reports of adverse events
- Strategies for follow up

The Current Regulatory Framework and its Global Impact

- Overview of European regulatory framework, including new EU pharmacovigilance legislation
- Implications for global environment - the links to ICH and CIOMs recommendations
- Inspections and penalties for non-compliance
- Pr! actical applications of definitions

European Post-Ma! rketing Pharmacovigilance Regulations
Overview of requirements which will include:

- The role of Pharmacovigilance Risk Assessment Committee and SCOPE initiative
- Quality Management Systems and the
- Pharmacovigilance System Master File (PSMF)
- QPPV
- Expedited Reporting solicited vs spontaneous
- Periodic reports and Signal Management
- Risk Management Plans and Risk Minimisation
- Post Authorisation Safety and Efficacy studies (PASS/PAES)
- Additional Monitoring
- Pharmacovigilance Inspections/audit
- Public Hearings
- Stakeholder involvement initiatives such as PROTECT, WEB-RADR

17.15 End of Day One and Drinks Reception

Day 2 Schedule

09.30 Pro-Active Pharmacovigilance Pre-and Post Marketing

- Anticipating drug safety issues in development of small molecules and biologics
- What specific and non-specific safety monitoring should be done?
- Handling safety sign! als in development
- Differences between pre-marketing studies and post-marketing experience

Risk/Benefit Assessment

- General principles
- Quantifying risk
- Taking action to optimise benefit/risk
- Monitoring the effectiveness of risk management measures

Clinical: Trial ADR Reporting Requirements

- IH E2A and general requirements
- Expedited reports
- EU Clinical Trials Directive and detailed guidance
- US IND requirements
- Development Safety Update Reports (DSURs)

Pharmacoepidemiology Studies - Basic Designs, Strenghts, Weaknesses and Examples

- Real world data is the King
- Randomisation in the real world
- Drugs and devices - its all exposure
- Tracking all patients?

Where are We Now with PSURs (or PBRERs)

- Evolution of the PSUR, PBRER and DSUR

- ICH E2C, Volume 9A, GVP Module VII and ICH E2C (R2)

What do we submit ! now and when is it required?

- Practical aspects of ! compilin g PSURs
- The link between DSURs, RMPs, PSURs, and Core Safety Information

17.00 Close of day two

Day 3 Schedule

09.30 Drug Surveillance in Countries Outside Europe

- US culture
- NDA and IND safety reporting
- Inspections
- Japan culture
- Post-marketing safety surveillance programmes in Japan
- Pharmacovigilance in other countries

Practicalities of Signal Detection

- Definitions of signals
- Regulatory guidances on signal detection by industry and regulators
- Resources for signal detection
- Quantitative v qualitative signal detection

Examples of Pharmacoepidemiological Studies Used in Risk Management

- Prescription event monitoring
- Prospective observational cohort studies
- Case control studies
- Drug registries (anti-TNFs)
- Pregnancy registries

Pract! icalities of Risk Management
A real world example of the development of a successful EU risk management plan

- Requirements of risk management plans from an industry point of view
- How to write a successful risk management plan
- Reporting results of outcomes of activities in the risk management plan
- Updating a risk management plan

Practical Pharmacovigilance Workshop
As requested by previous participants in this course, this session will comprise a practical case study with valuable hands-on experience covering:

- Handling an important safety alert from regulators
- Assessment of risk
- Determining measures to respond to previously unidentified risks
- Continuing assessmnet and communication of risk benefit

16.00 Close of day three

For more information about this conference visit http://www.researchandmarkets.com/research/2scctz/pharma! covigila nce

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl